Business
Final Results
GSK PLC reported strong 2025 performance with total sales of £32.7 billion, a 4% increase on an AER basis, driven by a 17% rise in Specialty Medicines sales to £13.5 billion, notably strong growth in Oncology (+43%) and HIV (+11%). Vaccines sales grew 2% to £9.2 billion, while General Medicines saw a 1% decline to £10.0 billion. Core operating profit increased by 11% and Core EPS by 12%, reflecting robust Specialty Medicines and Vaccines performance, alongside SG&A productivity and R&D investment. The company generated £8.9 billion in cash from operations and £4.0 billion in free cash flow, while reaffirming its long-term outlooks and providing 2026 guidance for turnover growth of 3-5% and core operating profit growth of 7-9% at CER. Disclaimer*
About this update from Gsk Plc
[{"type":"text","content":"\n\n\n\n\n\n\n\n\n\n\n\n\n\nGSK delivers strong 2025 performance and re-affirms long-term outlooks\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nSales, profit and earnings growth driven by strong Specialty Medicines performance\n\n\n\n\n•\n\n\nTotal 2025 sales £32.7 billion +4% AER; +7% CER\n\n\n\n\n•\n\n\nSpecialty Medicines sales £13.5 billion (+17%); Respiratory, Immunology & Inflammation £3.8 billion (+18%); Oncology £2.0 billion (+43%); HIV sales £7.7 billion (+11%)\n\n\n\n\n•\n\n\nVaccines sales £9.2 billion (+2%); Shingrix £3.6 billion (+8%); Meningitis vaccines £1.6 billion (+12%); and Arexvy £0.6 billion (+2%)\n\n\n\n\n•\n\n\nGeneral Medicines sales £10.0 billion (-1%); Trelegy £3.0 billion (+13%)\n\n\n\n\n•\n\n\nTotal operating profit >100% and Total EPS >100% driven by lower Significant legal expenses, lower CCL charges and higher other operating income, partly offset by intangible asset impairments\n\n\n\n\n•\n\n\nCore operating profit +11% and Core EPS +12% reflecting Specialty Medicines and Vaccines growth, SG&A productivity, higher royalty income and disciplined increased investment in R&D portfolio progression in Oncology and Vaccines\n\n\n\n\n•\n\n\nCash generated from operations of £8.9 billion with free cash flow of £4.0 billion\n\n\n\n\n(Financial Performance - 2025 results unless otherwise stated, growth % and commentary at CER as defined on page 53. In 2025 and Q4 2025, the adverse currency impact on AER versus CER primarily reflected the strengthening of Sterling against the USD. See page 11 for further details.)\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n2025\n\n\n\n\n\n\n\nQ4 2025\n\n\n\n\n\n\n\n\n\n£m\n\n\n\n\n\n\n\n% AER\n\n\n\n\n\n\n\n% CER\n\n\n\n\n\n\n\n£m\n\n\n\n\n\n\n\n% AER\n\n\n\n\n\n\n\n% CER\n\n\n\n\n\n\nTurnover\n\n\n\n\n32,667\n\n\n\n\n\n\n\n4\n\n\n\n\n\n\n\n7\n\n\n\n\n\n\n\n8,618\n\n\n\n\n\n\n\n6\n\n\n\n\n\n\n\n8\n\n\n\n\n\n\nTotal operating profit\n\n\n\n\n7,932\n\n\n\n\n\n\n\n97\n\n\n\n\n\n\n\n>100\n\n\n\n\n\n\n\n1,100\n\n\n\n\n\n\n\n58\n\n\n\n\n\n\n\n65\n\n\n\n\n\n\nTotal operating margin %\n\n\n\n\n24.3%\n\n\n\n\n\n\n\n11.5ppts\n\n\n\n\n\n\n\n11.9ppts\n\n\n\n\n\n\n\n12.8%\n\n\n\n\n\n\n\n4.2ppts\n\n\n\n\n\n\n\n4.6ppts\n\n\n\n\n\n\nTotal EPS\n\n\n\n\n141.1p\n\n\n\n\n\n\n\n>100\n\n\n\n\n\n\n\n>100\n\n\n\n\n\n\n\n...